Shopping Cart
- Remove All
Your shopping cart is currently empty
CDK12-IN-3
Catalog No. T14990Cas No. 2220184-50-7
CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.
CDK12-IN-3
Catalog No. T14990Cas No. 2220184-50-7
CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $132 | In Stock | |
| 5 mg | $328 | In Stock | |
| 10 mg | $538 | In Stock | |
| 25 mg | $1,130 | In Stock | |
| 50 mg | $1,890 | In Stock | |
| 100 mg | $2,500 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $363 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CDK12-IN-3"
Abemaciclib
Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedRibociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
- $36
Size
QTY
CitedCASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Palbociclib Cited
PD 0332991
T1785571190-30-2
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
- $48
Size
QTY
CitedDinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedAbemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedGW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
- $51
Size
QTY
Rafoxanide
T709322662-39-1
Rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. Rafoxanide is a salicylanilide used as an anthelmintic. It is used to treat fluke, hookworm and other infestations.
- $54
Size
QTY
Select Batch
Purity:99.85%
ee:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors. |
| Targets&IC50 | CDK12:491 nM |
| In vitro | CDK12-IN-3 is a highly selective inhibitor of CDK12, capable of effectively inhibiting the phosphorylation of Ser2 sites on the CTD repeat domain of RNA Polymerase II, exerting growth inhibitory effects on OV90 cells, and demonstrating acute cytotoxicity against THP1 cells[1]. |
| Molecular Weight | 470.52 |
| Formula | C23H28F2N8O |
| Cas No. | 2220184-50-7 |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (425.06 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CDK12-IN-3 | purchase CDK12-IN-3 | CDK12-IN-3 cost | order CDK12-IN-3 | CDK12-IN-3 chemical structure | CDK12-IN-3 in vitro | CDK12-IN-3 formula | CDK12-IN-3 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.